Results for tag: "Bulimia Nervosa Drug"

Bulimia Nervosa is an eating disorder characterized by recurrent episodes of binge eating followed by compensatory behaviors such as self-induced vomiting, misuse of laxatives, diuretics, or other medications, fasting, or excessive exercise. Clinical trials are conducted to evaluate the safety and efficacy of drugs for the treatment of Bulimia Nervosa. These trials are conducted in accordance with the principles of Good Clinical Practice and the ethical principles of the Declaration of Helsinki. The Bulimia Nervosa Drug market is composed of pharmaceutical companies, research organizations, and clinical research organizations that are involved in the development of drugs for the treatment of Bulimia Nervosa. These companies are involved in the research and development of new drugs, as well as the manufacture and marketing of existing drugs. Some companies in the Bulimia Nervosa Drug market include Pfizer, GlaxoSmithKline, Merck, Novartis, AstraZeneca, Eli Lilly, and Johnson & Johnson. Show Less Read more